• 1
    Lo JC, Chertow GM, Go AS, Hsu CY. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int 2005; 67: 104752.
  • 2
    Zoccali C, Mallamaci F. Thyroid, renal function and cardiac outcome. In: Iervasi G, Pingitore A, eds. Thyroid and Heart Failure. Dordrecht: Pringer Verlag, 2009; 191201.
  • 3
    Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 2005; 16: 278995.
  • 4
    Enia G, Panuccio V, Cutrupi S et al. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2007; 22: 53844.
  • 5
    Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P. Low triiodothyronine and survival in end-stage renal disease. Kidney Int 2006; 70: 5238.
  • 6
    Carrero JJ, Qureshi AR, Axelsson J et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007; 262: 690701.
  • 7
    Yilmaz MI, Sonmez A, Karaman M et al. Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol 2011; 33: 2532.
  • 8
    Zoccali C, Benedetto F, Mallamaci F et al. Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. J Hypertens 2006; 24: 203946.
  • 9
    Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int 2005; 67: 121633.
  • 10
    Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16(Suppl. 1): S838.
  • 11
    Papagianni A, Kokolina E, Kalovoulos M, Vainas A, Dimitriadis C, Memmos D. Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004; 19: 125863.
  • 12
    Stompor T, Krasniak A, Sulowicz W et al. Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. Nephrol Dial Transplant 2005; 20: 40412.
  • 13
    Stompor T, Rajzer M, Pasowicz M et al. Coronary artery calcification, common carotid artery intima-media thickness and aortic pulse wave velocity in patients on peritoneal dialysis. Int J Artif Organs 2006; 29: 73644.
  • 14
    Tatar E, Sezis DM, Kircelli F et al. The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients. Int Urol Nephrol 2012; 44: 6016.
  • 15
    Pingitore A, Galli E, Barison A et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93: 13518.
  • 16
    Meuwese CL, Carrero JJ, Cabezas-Rodriguez I et al. Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis? J Intern Med 2013; doi: 10.1111/joim.12107.
  • 17
    Abdelbaky A, Corsini E, Figueroa AL et al. Focal Arterial Inflammation Precedes Subsequent Calcification in the Same Location: a Longitudinal FDG-PET/CT Study. Circ Cardiovasc Imaging 2013 [Epub ahead of print].
  • 18
    Goldsmith D. Negative outcome studies in end-stage renal disease. Blood Purif 2008; 26: 636.
  • 19
    Arsanjani R, McCarren M, Bahl JJ, Goldman S. Translational potential of thyroid hormone and its analogs. J Mol Cell Cardiol 2011; 51: 50611.